As of November 16, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of DataMeds AI, Inc. The largest reported stake is Hyperscale Data, Inc.'s, at 9.99%. One filing is on record since November 10, 2026 (Schedule 13G, November 10, 2026).
Sell to companies like DataMeds AI, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Hyperscale Data, Inc. · Sole voting: 0 · Shared voting: 501,204 · Sole dispositive: 0 · Shared dispositive: 501,204 · SCHEDULE 13G, 2026-11-10
- · Holder: Hyperscale Data, Inc. · Percent: 9.99% · SCHEDULE 13G
- · Holder: Hyperscale Data, Inc. · Percent: 9.99% · Shares: 501,204 · SCHEDULE 13G
DataMeds AI, Inc. has 1 Schedule 13D or 13G filing on record since 2026-11-10. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Hyperscale Data, Inc. | 9.99% | 501,204 | SCHEDULE 13G, 2026-11-10 | 2026-05-27 |
Holding shares or following this stake? See who's behind DataMeds AI, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on DataMeds AI, Inc. and the records around it.
DataMeds AI, Inc. elsewhere on the record
- IPO filing Nov 2026
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Hyperscale Data, Inc. also filed stake reports on 4 other companies: Powell Max Ltd (Nov 2026), UNIVERSAL SAFETY PRODUCTS, INC. (Oct 2026), YY Group Holding Ltd. (Aug 2026)
Watch DataMeds AI, Inc.
Get an email when DataMeds AI, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on DataMeds AI, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on DataMeds AI, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DataMeds AI, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Hyperscale Data, Inc. | 0 | 501,204 | 0 | 501,204 | SCHEDULE 13G, 2026-11-10 |
The latest filing identifies DataMeds AI, Inc. by CUSIP 949503205 and gives its principal executive office as 3000 Bayport Drive, Suite 950, Tampa, FL 33607 (SCHEDULE 13G, 2026-11-10).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-11-10 | Hyperscale Data, Inc. | 9.99% | SCHEDULE 13G |
Also on the record for DataMeds AI, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 9, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 7, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 9, 2026 | Leadership change: Gary Herman appointed, Director | — | Leadership changes | Source |
| February 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 29, 2025 | IPO filing, Form 424B4 | $0.7 a share | IPO filings | Source |
| September 22, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 12, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 29, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 24, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 5, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 21, 2025 | IPO filing, Form 424B4 | $4.5 a share | IPO filings | Source |
The newest 12 of 20 records.
Tools for this story
Each opens in a new tab, filled in for DataMeds AI, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
